Showing 6,681 - 6,700 results of 9,864 for search '"drug"', query time: 0.10s Refine Results
  1. 6681

    Extended spectrum betalactamase and Carbapenemase producing gram negative bacteria from healthcare workers gowns at Debre Berhan Comprehensive Specialized Hospital, Ethiopia by Sisay Gebrish Sharew, Daniel Gebretsadik Weldehanna, Demissew Shenkute Gebreyes, Tsegahun Asfaw Abebe, Agumas Shibabaw

    Published 2025-01-01
    “…Among these, the most frequent isolates were E. coli, accounted 36 (30.8%) followed by K. pneumoniae, 26(22.2%). The overall multi-drug resistance (MDR) rate was 65 (55.6%). Of the 117 isolates, 17(14.5%) and 12(10.3%) were ESBL and carbapenemase producers respectively. …”
    Get full text
    Article
  2. 6682

    HTR1D regulates the PI3K/Akt signaling pathway to impact hepatocellular carcinoma development and resistance to sorafenib by Yingai Zhang, Yuting Zhang, Shuai Zhou, Mujeeb Ur Rehman, Fankai Lin, Jianquan Zhang, Hailong Zhou

    Published 2025-01-01
    “…Interference with HTR1D gene expression demonstrated its role in promoting HCC proliferation, migration, and drug resistance through the PI3K/Akt pathway. These findings were validated in a mouse model. …”
    Get full text
    Article
  3. 6683
  4. 6684

    Development and in vitro evaluation of biomimetic injectable hydrogels from decellularized human nerves for central nervous system regeneration by Gopal Agarwal, Kennedy Moes, Christine E. Schmidt

    Published 2025-04-01
    “…Overall, iHPN is a novel injectable hydrogel that has potential for minimally invasive CNS applications, such as a carrier for cell or drug delivery and/or a biomaterial to support axonal growth.…”
    Get full text
    Article
  5. 6685

    Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen by Michael L. McCaleb, Steven G. Hughes, Tamar R. Grossman, Ashley Frazer-Abel, Bill Jung, Lixuan Yin, Scott P. Henry, Brett P. Monia, Eugene Schneider, Richard Geary, Gary T. Brice

    Published 2025-03-01
    “…Healthy volunteers received either single or repeated (for 6 weeks) subcutaneous administrations of investigational drug or placebo. Safety and plasma complement protein levels were assessed throughout the studies and during 90-day follow-up periods. …”
    Get full text
    Article
  6. 6686

    Integrating RNA-seq and scRNA-seq to explore the prognostic features and immune landscape of exosome-related genes in breast cancer metastasis by Guanyou Huang, Yong Yu, Heng Su, Hongchuan Gan, Liangzhao Chu

    Published 2025-12-01
    “…Immune cell infiltration, immune escape and drug sensitivity disparities between high- and low-risk groups were assessed using CIBERSORT and single-sample gene set enrichment analysis (ssGSEA) methods. …”
    Get full text
    Article
  7. 6687
  8. 6688

    Modified Xiao-Qing-Long-decoction prevents inflammation and promotes Nur77 expression in mice with acute respiratory distress syndrome by inhibiting HDAC7 expression by Qing Zhang, Yafen Liu, Lu Jiang, Dongdong Yang

    Published 2025-12-01
    “…Importantly, the preventive effects of MXQLD in ARDS mice were reversed by HDAC7 over-expression.Discussion and conclusion MXQLD may prevent inflammation and promote Nur77 expression in ARDS by inhibiting HDAC7 expression, indicating that MXQLD may be a promising drug for preventing ARDS.…”
    Get full text
    Article
  9. 6689

    Synthesis and Evaluation of N-[1-(((3,4-Diphenylthiazol-2(3H)-ylidene)amino)methyl)cyclopentyl]acetamide Derivatives for the Treatment of Diseases Belonging to MAOs by Gülhan Turan-Zitouni, Aouatef Tabbi, Weiam Hussein, Abdullah Burak Karaduman, Begüm Nurpelin Sağlık, Yusuf Özkay

    Published 2018-01-01
    “…In the hMAO-A inhibition assay, compounds 4a, 4b, 4c, and 4i exhibited similar activity with standard drug moclobemide (IC50 = 6.061 ± 0.262 µM) with IC50 values of 7.06 ± 0.18 µM, 6.56 ± 0.20 µM, 6.78 ± 0.15 µM, and 7.09 ± 0.17 µM, respectively. …”
    Get full text
    Article
  10. 6690

    Impact of adjuvant trastuzumab therapy and its discontinuation on cardiac function and mortality in patients with early-stage breast cancer: An analysis based on the Japanese Recei... by Keiko Miyazato, Hiroshi Ohtsu, Akihiko Shimomura, Naohiro Yonemoto, Chikako Shimizu, Kazuhiro Sase, Shinichiro Ueda

    Published 2025-02-01
    “…Our findings suggest that discontinuation of trastuzumab treatment worsens patient prognosis due to insufficient treatment of breast cancer rather than due to the cardiovascular toxicity of the drug.…”
    Get full text
    Article
  11. 6691

    Evaluation of Relationship between Schemas and Panic Disorder through a Case Treated with Schema Therapy by Esra Yancar Demir, Gonca Soygüt

    Published 2014-08-01
    “…Discussion: Early maladaptive schemas and inadaptive ways of behaviors that has been developed by patients to handle these schemas may underly the axis I disorder symptoms such as anxiety, depression, drug abuse and psychosomatic disorders. As we look have a look at our patient, it can be said that her seperation with parents before elementary school may have led to her schemas of desertion and distrust and also teacher being over guarding at the levels of harming sovereignty to compensate the absence of the parents forms the basis of schemas of dependence / incompatence, being harmed and weakness against ilnesses. …”
    Get full text
    Article
  12. 6692
  13. 6693

    Long-Term Safety and Effectiveness of Canakinumab in Patients with MKD/HIDS: Interim Analysis of the RELIANCE Registry by Prasad T. Oommen, Tilmann Kallinich, Juergen Rech, Norbert Blank, Julia Weber-Arden, Jasmin B. Kuemmerle-Deschner

    Published 2024-12-01
    “…Canakinumab was well tolerated, with seven (87.5%) patients reporting 48 adverse events (incidence rate/100 patient years: 218.1). No serious adverse drug reactions were reported. Patients continued to receive vaccinations during long-term treatment with canakinumab. …”
    Get full text
    Article
  14. 6694

    NIPAL1 as a prognostic biomarker associated with pancreatic adenocarcinoma progression and immune infiltration by Youlong Zhu, Zongze Qi, Shaoqi Zu, Fangchao Yang, Yanming Wang, Lei Zhu, Xintong Li, Ruixue Li, Hong Zhu

    Published 2025-01-01
    “…Subsequently, we predicted five small-molecule drugs targeted at NIPAL1 using molecular docking. …”
    Get full text
    Article
  15. 6695

    Hospital-Based Air-Borne and Surface-Borne Bacterial Pathogens and Their Antimicrobial Profiles in Wolaita Sodo, Southern Ethiopia by Chemere Madebo, Admasu Haile, Temesgen Eticha, Fithamlak Solomon

    Published 2022-01-01
    “…The Mueller-Hinton agar was used to detect the drug susceptibility pattern of bacteria by using the Kirby-Bauer disc diffusion method. …”
    Get full text
    Article
  16. 6696

    A Cross-Sectional Study on the Affordable Care Act from the Perspective of People Living with HIV: The Interplay between Knowledge, Stigma, Trust, and Attitudes by Christopher Kaperak, Sarah Elwood, Tamara Saint-Surin, Christopher Winstead-Derlega, Robert O. Brennan, Rebecca Dillingham, Kathleen A. McManus

    Published 2020-01-01
    “…Background. Many AIDS Drug Assistance Programs (ADAPs) purchased Affordable Care Act (ACA) Qualified Health Plans (QHPs) for low-income people living with HIV (PLWH). …”
    Get full text
    Article
  17. 6697

    Integrative analysis of anoikis-related prognostic signature to evaluate the immune landscape and predict therapeutic response in stomach adenocarcinoma by Ziyi Zhou, Lanlan Yang, Yuan Fang, Rongzhong Xu, Xi Wang, Yuli Wang, Zhihong Fang

    Published 2025-02-01
    “…The prognostic signature indicated that the low-risk subgroup had better outcomes and significant correlations with tumor microenvironment, immune landscape, immunotherapy response, and drug sensitivity. In addition, single-cell analysis displayed the cell types, the subcellular localization of prognostic genes, and the cellular interaction to reveal the potential molecular communication mechanism of anoikis resistance. …”
    Get full text
    Article
  18. 6698

    Hypertensive load predicts recovery of renal function for patients undergoing revascularisation for renal artery stenosis by Ben Edgar, Rob Pearson, Andrew Jackson, Callum Stove, Ram Kasthuri, Keith Hussey, Christian Delles, Colin Geddes, Patrick Mark, Giles Roditi, Linsay McCallum, David B. Kingsmore

    Published 2025-01-01
    “…The Hypertensive Index (HTi), a combined measure of systolic blood pressure and antihypertensive drug load, was used as a measure of pre-intervention hypertensive response. 75 patients had intervention for renal impairment over 15 years (68 endovascular, 7 open). …”
    Get full text
    Article
  19. 6699

    The XIAP inhibitor AZD5582 improves the treatment effect of microwave ablation on hepatocellular carcinoma by Wenhui Wang, Fuyuan Wu, Zhe Wu, Mengfan Zhang, Qiang Lu

    Published 2025-01-01
    “…The IMWA model of C57BL/6 and NTG mice were established, and AZD5582 was used in combination to evaluate the inhibitory and pro-apoptotic effects of different treatment regimens on tumor growth and to detect the local immune infiltration of C57BL/6 tumors. Finally, AZD5582 drug toxicity was detected to confirm its feasibility.ResultsXIAP protein expression is significantly increased in recurrent hepatocellular carcinoma tissues of patients who previously received microwave ablation therapy. …”
    Get full text
    Article
  20. 6700

    Development and validation of an LC-MS/MS method for the simultaneous estimation of tadalafil and macitentan in rat plasma: Greenness assessment and design of experiment approach by Sravanthi Gandu, Kumaraswamy Gandla, Lalitha Repudi

    Published 2025-03-01
    “…Precision, expressed as %CV, was consistently below 15% for both intra- and inter-day variability. Drug recovery exceeded 98%, and stability tests demonstrated robustness under various conditions, with %CV values remaining under 15%. …”
    Get full text
    Article